Access the full text.
Sign up today, get DeepDyve free for 14 days.
O. Aktas, P. Küry, B. Kieseier, H. Hartung (2010)
Fingolimod is a potential novel therapy for multiple sclerosisNature Reviews Neurology, 6
Haiping Zheng, Chunli Chen, Jie Zhang, Zhiping Hu (2016)
Mechanism and Therapy of Brain Edema after Intracerebral HemorrhageCerebrovascular Diseases, 42
Minshu Li, Zhiguo Li, Honglei Ren, Wei-Na Jin, Kristofer Wood, Qiang Liu, K. Sheth, F. Shi (2016)
Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhageJournal of Cerebral Blood Flow & Metabolism, 37
Sebastian Urday, L. Beslow, F. Dai, Fan Zhang, Thomas Battey, A. Vashkevich, A. Ayres, A. Leasure, M. Selim, J. Simard, J. Rosand, W. Kimberly, K. Sheth (2016)
Rate of Perihematomal Edema Expansion Predicts Outcome After Intracerebral HemorrhageCritical Care Medicine, 44
(2016)
VISTA ICH Collaborators
(LiM., LiZ., RenH., JinW.N., WoodK., LiuQ., ShethK.N., and ShiF.D. 2017a Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 37:2383–2395. 10.1177/0271678X1666655127596835)
LiM., LiZ., RenH., JinW.N., WoodK., LiuQ., ShethK.N., and ShiF.D. 2017a Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 37:2383–2395. 10.1177/0271678X1666655127596835LiM., LiZ., RenH., JinW.N., WoodK., LiuQ., ShethK.N., and ShiF.D. 2017a Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 37:2383–2395. 10.1177/0271678X1666655127596835, LiM., LiZ., RenH., JinW.N., WoodK., LiuQ., ShethK.N., and ShiF.D. 2017a Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 37:2383–2395. 10.1177/0271678X1666655127596835
(LodoenM., OgasawaraK., HamermanJ.A., AraseH., HouchinsJ.P., MocarskiE.S., and LanierL.L. 2003 NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197:1245–1253. 10.1084/jem.2002197312756263)
LodoenM., OgasawaraK., HamermanJ.A., AraseH., HouchinsJ.P., MocarskiE.S., and LanierL.L. 2003 NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197:1245–1253. 10.1084/jem.2002197312756263LodoenM., OgasawaraK., HamermanJ.A., AraseH., HouchinsJ.P., MocarskiE.S., and LanierL.L. 2003 NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197:1245–1253. 10.1084/jem.2002197312756263, LodoenM., OgasawaraK., HamermanJ.A., AraseH., HouchinsJ.P., MocarskiE.S., and LanierL.L. 2003 NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197:1245–1253. 10.1084/jem.2002197312756263
F. Shi, H. Ljunggren, A. Cava, L. Kaer (2011)
Organ-specific features of natural killer cellsNature Reviews. Immunology, 11
Unpaired two-tailed t test. Data are presented as mean ± SD
(LiuQ., JinW.N., LiuY., ShiK., SunH., ZhangF., ZhangC., GonzalesR.J., ShethK.N., La CavaA., 2017 Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations. Immunity. 46:474–487. 10.1016/j.immuni.2017.02.01528314594)
LiuQ., JinW.N., LiuY., ShiK., SunH., ZhangF., ZhangC., GonzalesR.J., ShethK.N., La CavaA., 2017 Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations. Immunity. 46:474–487. 10.1016/j.immuni.2017.02.01528314594LiuQ., JinW.N., LiuY., ShiK., SunH., ZhangF., ZhangC., GonzalesR.J., ShethK.N., La CavaA., 2017 Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations. Immunity. 46:474–487. 10.1016/j.immuni.2017.02.01528314594, LiuQ., JinW.N., LiuY., ShiK., SunH., ZhangF., ZhangC., GonzalesR.J., ShethK.N., La CavaA., 2017 Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations. Immunity. 46:474–487. 10.1016/j.immuni.2017.02.01528314594
Jian Wang (2010)
Preclinical and clinical research on inflammation after intracerebral hemorrhageProgress in Neurobiology, 92
(ZhengH., ChenC., ZhangJ., and HuZ. 2016 Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage. Cerebrovasc. Dis. 42:155–169. 10.1159/00044517027110940)
ZhengH., ChenC., ZhangJ., and HuZ. 2016 Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage. Cerebrovasc. Dis. 42:155–169. 10.1159/00044517027110940ZhengH., ChenC., ZhangJ., and HuZ. 2016 Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage. Cerebrovasc. Dis. 42:155–169. 10.1159/00044517027110940, ZhengH., ChenC., ZhangJ., and HuZ. 2016 Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage. Cerebrovasc. Dis. 42:155–169. 10.1159/00044517027110940
(HanleyD.F., ThompsonR.E., RosenblumM., YenokyanG., LaneK., McBeeN., MayoS.W., Bistran-HallA.J., GandhiD., MouldW.A., ; MISTIE III Investigators 2019 Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 393:1021–1032. 10.1016/S0140-6736(19)30195-330739747)
HanleyD.F., ThompsonR.E., RosenblumM., YenokyanG., LaneK., McBeeN., MayoS.W., Bistran-HallA.J., GandhiD., MouldW.A., ; MISTIE III Investigators 2019 Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 393:1021–1032. 10.1016/S0140-6736(19)30195-330739747HanleyD.F., ThompsonR.E., RosenblumM., YenokyanG., LaneK., McBeeN., MayoS.W., Bistran-HallA.J., GandhiD., MouldW.A., ; MISTIE III Investigators 2019 Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 393:1021–1032. 10.1016/S0140-6736(19)30195-330739747, HanleyD.F., ThompsonR.E., RosenblumM., YenokyanG., LaneK., McBeeN., MayoS.W., Bistran-HallA.J., GandhiD., MouldW.A., ; MISTIE III Investigators 2019 Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 393:1021–1032. 10.1016/S0140-6736(19)30195-330739747
M. Selim, L. Foster, C. Moy, G. Xi, M. Hill, L. Morgenstern, S. Greenberg, M. James, Vineeta Singh, W. Clark, Casey Norton, Y. Palesch, S. Yeatts, M. Dolan, Erlinda Yeh, K. Sheth, K. Kunze, S. Muehlschlegel, I. Nieto, J. Claassen, C. Falo, David Huang, Anne Beckwith, S. Messé, M. Yates, Kristine O’Phelan, Andrea Escobar, K. Becker, Patricia Tanzi, N. Gonzales, Chad Tremont, C. Venkatasubramanian, Rosita Thiessen, Supriya Save, Steven Verrault, Karine Collard, M. DeGeorgia, V. Cwiklinski, Bradford Thompson, Lesley Wasilewski, Charles Andrews, R. Burfeind, M. Torbey, Mohammad Hamed, K. Butcher, L. Sivakumar, N. Varelas, Kathleen Mays-Wilson, E. Leira, Heena Olalde, S. Silliman, R. Calhoun, N. Dangayach, Ricardo Renvill, R. Malhotra, Kristina Kordesch, A. Lord, Thomas Calahan, R. Geocadin, Michelle Parish, James Frey, M. Harrigan, D. Leifer, Ryna Mathias, Michaela Schneck, T. Bernier, Sergio Gonzales-Arias, Josette Elysee, G. Lopez, J. Volgi, R. Brown, Sara Jasak, Stephen Phillips, J. Jarrett, J. Gomes, Moneen McBride, François Aldrich, Charlene Aldrich, J. Kornbluth, M. Bettle, J. Goldstein, G. Tirrell, Qaisar Shaw, K. Jonczak (2019)
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trialThe Lancet Neurology, 18
(ThiexR., and TsirkaS.E. 2007 Brain edema after intracerebral hemorrhage: mechanisms, treatment options, management strategies, and operative indications. Neurosurg. Focus. 22 E6 10.3171/foc.2007.22.5.7)
ThiexR., and TsirkaS.E. 2007 Brain edema after intracerebral hemorrhage: mechanisms, treatment options, management strategies, and operative indications. Neurosurg. Focus. 22 E6 10.3171/foc.2007.22.5.7ThiexR., and TsirkaS.E. 2007 Brain edema after intracerebral hemorrhage: mechanisms, treatment options, management strategies, and operative indications. Neurosurg. Focus. 22 E6 10.3171/foc.2007.22.5.7, ThiexR., and TsirkaS.E. 2007 Brain edema after intracerebral hemorrhage: mechanisms, treatment options, management strategies, and operative indications. Neurosurg. Focus. 22 E6 10.3171/foc.2007.22.5.7
(LiuQ., SanaiN., JinW.N., La CavaA., Van KaerL., and ShiF.D. 2016 Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat. Neurosci. 19:243–252. 10.1038/nn.421126752157)
LiuQ., SanaiN., JinW.N., La CavaA., Van KaerL., and ShiF.D. 2016 Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat. Neurosci. 19:243–252. 10.1038/nn.421126752157LiuQ., SanaiN., JinW.N., La CavaA., Van KaerL., and ShiF.D. 2016 Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat. Neurosci. 19:243–252. 10.1038/nn.421126752157, LiuQ., SanaiN., JinW.N., La CavaA., Van KaerL., and ShiF.D. 2016 Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat. Neurosci. 19:243–252. 10.1038/nn.421126752157
Enrichment of immune signatures in brain-infiltrating NK cells following ICH. (A) ICH was induced in C57BL/6 mice by collagenase injection
I. Moxon-Emre, L. Schlichter (2011)
Neutrophil Depletion Reduces Blood-Brain Barrier Breakdown, Axon Injury, and Inflammation After Intracerebral HemorrhageJournal of Neuropathology and Experimental Neurology, 70
(GanY., LiuQ., WuW., YinJ.X., BaiX.F., ShenR., WangY., ChenJ., La CavaA., Poursine-LaurentJ., 2014 Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc. Natl. Acad. Sci. USA. 111:2704–2709. 10.1073/pnas.131594311124550298)
GanY., LiuQ., WuW., YinJ.X., BaiX.F., ShenR., WangY., ChenJ., La CavaA., Poursine-LaurentJ., 2014 Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc. Natl. Acad. Sci. USA. 111:2704–2709. 10.1073/pnas.131594311124550298GanY., LiuQ., WuW., YinJ.X., BaiX.F., ShenR., WangY., ChenJ., La CavaA., Poursine-LaurentJ., 2014 Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc. Natl. Acad. Sci. USA. 111:2704–2709. 10.1073/pnas.131594311124550298, GanY., LiuQ., WuW., YinJ.X., BaiX.F., ShenR., WangY., ChenJ., La CavaA., Poursine-LaurentJ., 2014 Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc. Natl. Acad. Sci. USA. 111:2704–2709. 10.1073/pnas.131594311124550298
Journal of Experimental Medicine 15 of 15 Natural killer cells in intracerebral hemorrhage
Sebastian Urday, W. Kimberly, L. Beslow, A. Vortmeyer, M. Selim, J. Rosand, J. Simard, K. Sheth (2015)
Targeting secondary injury in intracerebral haemorrhage—perihaematomal oedemaNature Reviews Neurology, 11
(BobingerT., ManaenkoA., BurkardtP., BeuscherV., SprügelM.I., RoederS.S., BäuerleT., SeylerL., NagelA.M., LinkerR.A., 2019 Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage. Stroke. 50:3246–3254. 10.1161/STROKEAHA.119.02713431558140)
BobingerT., ManaenkoA., BurkardtP., BeuscherV., SprügelM.I., RoederS.S., BäuerleT., SeylerL., NagelA.M., LinkerR.A., 2019 Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage. Stroke. 50:3246–3254. 10.1161/STROKEAHA.119.02713431558140BobingerT., ManaenkoA., BurkardtP., BeuscherV., SprügelM.I., RoederS.S., BäuerleT., SeylerL., NagelA.M., LinkerR.A., 2019 Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage. Stroke. 50:3246–3254. 10.1161/STROKEAHA.119.02713431558140, BobingerT., ManaenkoA., BurkardtP., BeuscherV., SprügelM.I., RoederS.S., BäuerleT., SeylerL., NagelA.M., LinkerR.A., 2019 Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage. Stroke. 50:3246–3254. 10.1161/STROKEAHA.119.02713431558140
Eric Long, H. Kim, Dongfang Liu, M. Peterson, S. Rajagopalan (2013)
Controlling natural killer cell responses: integration of signals for activation and inhibition.Annual review of immunology, 31
E. Mracsko, Ehsan Javidi, S. Na, A. Kahn, A. Liesz, R. Veltkamp (2014)
Leukocyte Invasion of the Brain After Experimental Intracerebral Hemorrhage in MiceStroke, 45
Ying Fu, J. Hao, Ningnannan Zhang, L. Ren, Na Sun, Yu-jing Li, Yaping Yan, Deren Huang, Chunshui Yu, F. Shi (2014)
Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study.JAMA neurology, 71 9
J. Aronowski, Xiurong Zhao (2011)
Molecular pathophysiology of cerebral hemorrhage: secondary brain injury.Stroke, 42 6
(MracskoE., and VeltkampR. 2014 Neuroinflammation after intracerebral hemorrhage. Front. Cell. Neurosci. 8:388 10.3389/fncel.2014.0038825477782)
MracskoE., and VeltkampR. 2014 Neuroinflammation after intracerebral hemorrhage. Front. Cell. Neurosci. 8:388 10.3389/fncel.2014.0038825477782MracskoE., and VeltkampR. 2014 Neuroinflammation after intracerebral hemorrhage. Front. Cell. Neurosci. 8:388 10.3389/fncel.2014.0038825477782, MracskoE., and VeltkampR. 2014 Neuroinflammation after intracerebral hemorrhage. Front. Cell. Neurosci. 8:388 10.3389/fncel.2014.0038825477782
(SelimM., FosterL.D., MoyC.S., XiG., HillM.D., MorgensternL.B., GreenbergS.M., JamesM.L., SinghV., ClarkW.M., ; i-DEF Investigators 2019 Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 18:428–438. 10.1016/S1474-4422(19)30069-930898550)
SelimM., FosterL.D., MoyC.S., XiG., HillM.D., MorgensternL.B., GreenbergS.M., JamesM.L., SinghV., ClarkW.M., ; i-DEF Investigators 2019 Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 18:428–438. 10.1016/S1474-4422(19)30069-930898550SelimM., FosterL.D., MoyC.S., XiG., HillM.D., MorgensternL.B., GreenbergS.M., JamesM.L., SinghV., ClarkW.M., ; i-DEF Investigators 2019 Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 18:428–438. 10.1016/S1474-4422(19)30069-930898550, SelimM., FosterL.D., MoyC.S., XiG., HillM.D., MorgensternL.B., GreenbergS.M., JamesM.L., SinghV., ClarkW.M., ; i-DEF Investigators 2019 Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 18:428–438. 10.1016/S1474-4422(19)30069-930898550
Honglei Ren, Y. Kong, Zhijia Liu, D. Zang, Xiaoxia Yang, Kristofer Wood, Minshu Li, Qiang Liu (2018)
Selective NLRP3 (Pyrin Domain–Containing Protein 3) Inflammasome Inhibitor Reduces Brain Injury After Intracerebral HemorrhageStroke, 49
Xiao-dong Kong, Sheng Bai, Xin Chen, Hui-jie Wei, Wei-Na Jin, Minshu Li, Yaping Yan, F. Shi (2014)
Alterations of natural killer cells in traumatic brain injuryNeuroscience Bulletin, 30
C. Iadecola, J. Anrather (2011)
The immunology of stroke: from mechanisms to translationNature medicine, 17
(KongX.D., BaiS., ChenX., WeiH.J., JinW.N., LiM.S., YanY., and ShiF.D. 2014 Alterations of natural killer cells in traumatic brain injury. Neurosci. Bull. 30:903–912. 10.1007/s12264-014-1481-925446874)
KongX.D., BaiS., ChenX., WeiH.J., JinW.N., LiM.S., YanY., and ShiF.D. 2014 Alterations of natural killer cells in traumatic brain injury. Neurosci. Bull. 30:903–912. 10.1007/s12264-014-1481-925446874KongX.D., BaiS., ChenX., WeiH.J., JinW.N., LiM.S., YanY., and ShiF.D. 2014 Alterations of natural killer cells in traumatic brain injury. Neurosci. Bull. 30:903–912. 10.1007/s12264-014-1481-925446874, KongX.D., BaiS., ChenX., WeiH.J., JinW.N., LiM.S., YanY., and ShiF.D. 2014 Alterations of natural killer cells in traumatic brain injury. Neurosci. Bull. 30:903–912. 10.1007/s12264-014-1481-925446874
(LiM., RenH., ShethK.N., ShiF.D., and LiuQ. 2017c A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB J. 31:3278–3287. 10.1096/fj.201601377RR28416580)
LiM., RenH., ShethK.N., ShiF.D., and LiuQ. 2017c A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB J. 31:3278–3287. 10.1096/fj.201601377RR28416580LiM., RenH., ShethK.N., ShiF.D., and LiuQ. 2017c A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB J. 31:3278–3287. 10.1096/fj.201601377RR28416580, LiM., RenH., ShethK.N., ShiF.D., and LiuQ. 2017c A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB J. 31:3278–3287. 10.1096/fj.201601377RR28416580
and brain water content (C) in indicated groups of Rag2 −/− γc −/− mice 24 h after ICH. n = 10/group. Data are from three independently repeated experiments
(Moxon-EmreI., and SchlichterL.C. 2011 Neutrophil depletion reduces blood-brain barrier breakdown, axon injury, and inflammation after intracerebral hemorrhage. J. Neuropathol. Exp. Neurol. 70:218–235. 10.1097/NEN.0b013e31820d94a521293296)
Moxon-EmreI., and SchlichterL.C. 2011 Neutrophil depletion reduces blood-brain barrier breakdown, axon injury, and inflammation after intracerebral hemorrhage. J. Neuropathol. Exp. Neurol. 70:218–235. 10.1097/NEN.0b013e31820d94a521293296Moxon-EmreI., and SchlichterL.C. 2011 Neutrophil depletion reduces blood-brain barrier breakdown, axon injury, and inflammation after intracerebral hemorrhage. J. Neuropathol. Exp. Neurol. 70:218–235. 10.1097/NEN.0b013e31820d94a521293296, Moxon-EmreI., and SchlichterL.C. 2011 Neutrophil depletion reduces blood-brain barrier breakdown, axon injury, and inflammation after intracerebral hemorrhage. J. Neuropathol. Exp. Neurol. 70:218–235. 10.1097/NEN.0b013e31820d94a521293296
T. Bobinger, A. Manaenko, P. Burkardt, Vanessa Beuscher, M. Sprügel, S. Roeder, T. Bäuerle, L. Seyler, A. Nagel, Ralf Linker, Ralf Linker, T. Engelhorn, A. Dörfler, S. Hörsten, S. Schwab, H. Huttner (2019)
Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage.Stroke
(MurthyS.B., UrdayS., BeslowL.A., DawsonJ., LeesK., KimberlyW.T., IadecolaC., KamelH., HanleyD.F., ShethK.N., ; VISTA ICH Collaborators 2016 Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry. 87:1169–1173. 10.1136/jnnp-2016-31365327466360)
MurthyS.B., UrdayS., BeslowL.A., DawsonJ., LeesK., KimberlyW.T., IadecolaC., KamelH., HanleyD.F., ShethK.N., ; VISTA ICH Collaborators 2016 Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry. 87:1169–1173. 10.1136/jnnp-2016-31365327466360MurthyS.B., UrdayS., BeslowL.A., DawsonJ., LeesK., KimberlyW.T., IadecolaC., KamelH., HanleyD.F., ShethK.N., ; VISTA ICH Collaborators 2016 Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry. 87:1169–1173. 10.1136/jnnp-2016-31365327466360, MurthyS.B., UrdayS., BeslowL.A., DawsonJ., LeesK., KimberlyW.T., IadecolaC., KamelH., HanleyD.F., ShethK.N., ; VISTA ICH Collaborators 2016 Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry. 87:1169–1173. 10.1136/jnnp-2016-31365327466360
(UrdayS., KimberlyW.T., BeslowL.A., VortmeyerA.O., SelimM.H., RosandJ., SimardJ.M., and ShethK.N. 2015 Targeting secondary injury in intracerebral haemorrhage--perihaematomal oedema. Nat. Rev. Neurol. 11:111–122. 10.1038/nrneurol.2014.26425623787)
UrdayS., KimberlyW.T., BeslowL.A., VortmeyerA.O., SelimM.H., RosandJ., SimardJ.M., and ShethK.N. 2015 Targeting secondary injury in intracerebral haemorrhage--perihaematomal oedema. Nat. Rev. Neurol. 11:111–122. 10.1038/nrneurol.2014.26425623787UrdayS., KimberlyW.T., BeslowL.A., VortmeyerA.O., SelimM.H., RosandJ., SimardJ.M., and ShethK.N. 2015 Targeting secondary injury in intracerebral haemorrhage--perihaematomal oedema. Nat. Rev. Neurol. 11:111–122. 10.1038/nrneurol.2014.26425623787, UrdayS., KimberlyW.T., BeslowL.A., VortmeyerA.O., SelimM.H., RosandJ., SimardJ.M., and ShethK.N. 2015 Targeting secondary injury in intracerebral haemorrhage--perihaematomal oedema. Nat. Rev. Neurol. 11:111–122. 10.1038/nrneurol.2014.26425623787
V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, P. Burtin (2010)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 9
(ZhangY., GaoZ., WangD., ZhangT., SunB., MuL., WangJ., LiuY., KongQ., LiuX., 2014 Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10. J. Neuroinflammation. 11:79 10.1186/1742-2094-11-7924742325)
ZhangY., GaoZ., WangD., ZhangT., SunB., MuL., WangJ., LiuY., KongQ., LiuX., 2014 Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10. J. Neuroinflammation. 11:79 10.1186/1742-2094-11-7924742325ZhangY., GaoZ., WangD., ZhangT., SunB., MuL., WangJ., LiuY., KongQ., LiuX., 2014 Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10. J. Neuroinflammation. 11:79 10.1186/1742-2094-11-7924742325, ZhangY., GaoZ., WangD., ZhangT., SunB., MuL., WangJ., LiuY., KongQ., LiuX., 2014 Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10. J. Neuroinflammation. 11:79 10.1186/1742-2094-11-7924742325
(LiM., LiZ., YaoY., JinW.N., WoodK., LiuQ., ShiF.D., and HaoJ. 2017b Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc. Natl. Acad. Sci. USA. 114:E396–E405. 10.1073/pnas.161293011427994144)
LiM., LiZ., YaoY., JinW.N., WoodK., LiuQ., ShiF.D., and HaoJ. 2017b Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc. Natl. Acad. Sci. USA. 114:E396–E405. 10.1073/pnas.161293011427994144LiM., LiZ., YaoY., JinW.N., WoodK., LiuQ., ShiF.D., and HaoJ. 2017b Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc. Natl. Acad. Sci. USA. 114:E396–E405. 10.1073/pnas.161293011427994144, LiM., LiZ., YaoY., JinW.N., WoodK., LiuQ., ShiF.D., and HaoJ. 2017b Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc. Natl. Acad. Sci. USA. 114:E396–E405. 10.1073/pnas.161293011427994144
Minshu Li, Zhiguo Li, Yang Yao, Wei-Na Jin, Kristofer Wood, Qiang Liu, F. Shi, J. Hao (2016)
Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunityProceedings of the National Academy of Sciences, 114
(SansingL.H., HarrisT.H., KasnerS.E., HunterC.A., and KarikoK. 2011 Neutrophil depletion diminishes monocyte infiltration and improves functional outcome after experimental intracerebral hemorrhage. Acta Neurochir. Suppl. (Wien). 111:173–178. 10.1007/978-3-7091-0693-8_29)
SansingL.H., HarrisT.H., KasnerS.E., HunterC.A., and KarikoK. 2011 Neutrophil depletion diminishes monocyte infiltration and improves functional outcome after experimental intracerebral hemorrhage. Acta Neurochir. Suppl. (Wien). 111:173–178. 10.1007/978-3-7091-0693-8_29SansingL.H., HarrisT.H., KasnerS.E., HunterC.A., and KarikoK. 2011 Neutrophil depletion diminishes monocyte infiltration and improves functional outcome after experimental intracerebral hemorrhage. Acta Neurochir. Suppl. (Wien). 111:173–178. 10.1007/978-3-7091-0693-8_29, SansingL.H., HarrisT.H., KasnerS.E., HunterC.A., and KarikoK. 2011 Neutrophil depletion diminishes monocyte infiltration and improves functional outcome after experimental intracerebral hemorrhage. Acta Neurochir. Suppl. (Wien). 111:173–178. 10.1007/978-3-7091-0693-8_29
Jiang Zhu, Xiaopei Huang, Yiping Yang (2010)
NKG2D Is Required for NK Cell Activation and Function in Response to E1-Deleted AdenovirusThe Journal of Immunology, 185
(AronowskiJ., and ZhaoX. 2011 Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke. 42:1781–1786. 10.1161/STROKEAHA.110.59671821527759)
AronowskiJ., and ZhaoX. 2011 Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke. 42:1781–1786. 10.1161/STROKEAHA.110.59671821527759AronowskiJ., and ZhaoX. 2011 Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke. 42:1781–1786. 10.1161/STROKEAHA.110.59671821527759, AronowskiJ., and ZhaoX. 2011 Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke. 42:1781–1786. 10.1161/STROKEAHA.110.59671821527759
M. Lodoen, K. Ogasawara, J. Hamerman, H. Arase, J. Houchins, E. Mocarski, L. Lanier (2003)
NKG2D-mediated Natural Killer Cell Protection Against Cytomegalovirus Is Impaired by Viral gp40 Modulation of Retinoic Acid Early Inducible 1 Gene MoleculesThe Journal of Experimental Medicine, 197
Qiang Liu, N. Sanai, Wei-Na Jin, A. Cava, L. Kaer, F. Shi (2016)
Neural stem cells sustain natural killer cells that dictate recovery from brain inflammationNature Neuroscience, 19
Gurman Kaur, J. Trowsdale, L. Fugger (2013)
Natural killer cells and their receptors in multiple sclerosis.Brain : a journal of neurology, 136 Pt 9
R. Thiex, S. Tsirka (2007)
Brain edema after intracerebral hemorrhage: mechanisms, treatment options, management strategies, and operative indications.Neurosurgical focus, 22 5
A. Corrigan, Roshan Shrestha, I. Zulkipli, N. Hiroi, Yingjun Liu, Naoka Tamura, Bing Yang, Jessica Patel, Akira Funahashi, A. Donald (2013)
Supplemental Material to
(CrinierA., MilpiedP., EscalièreB., PiperoglouC., GallusoJ., BalsamoA., SpinelliL., Cervera-MarzalI., EbboM., Girard-MadouxM., 2018 High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice. Immunity. 49:971–986.e5. 10.1016/j.immuni.2018.09.00930413361)
CrinierA., MilpiedP., EscalièreB., PiperoglouC., GallusoJ., BalsamoA., SpinelliL., Cervera-MarzalI., EbboM., Girard-MadouxM., 2018 High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice. Immunity. 49:971–986.e5. 10.1016/j.immuni.2018.09.00930413361CrinierA., MilpiedP., EscalièreB., PiperoglouC., GallusoJ., BalsamoA., SpinelliL., Cervera-MarzalI., EbboM., Girard-MadouxM., 2018 High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice. Immunity. 49:971–986.e5. 10.1016/j.immuni.2018.09.00930413361, CrinierA., MilpiedP., EscalièreB., PiperoglouC., GallusoJ., BalsamoA., SpinelliL., Cervera-MarzalI., EbboM., Girard-MadouxM., 2018 High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice. Immunity. 49:971–986.e5. 10.1016/j.immuni.2018.09.00930413361
S. Murthy, Sebastian Urday, L. Beslow, J. Dawson, K. Lees, W. Kimberly, C. Iadecola, H. Kamel, D. Hanley, K. Sheth, W. Ziai (2016)
Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhageJournal of Neurology, Neurosurgery & Psychiatry, 87
Kevin Lee, N. Kawai, Seoung-Hoi Kim, O. Sagher, J. Hoff (1996)
Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model.Journal of neurosurgery, 86 2
(IadecolaC., and AnratherJ. 2011 The immunology of stroke: from mechanisms to translation. Nat. Med. 17:796–808. 10.1038/nm.239921738161)
IadecolaC., and AnratherJ. 2011 The immunology of stroke: from mechanisms to translation. Nat. Med. 17:796–808. 10.1038/nm.239921738161IadecolaC., and AnratherJ. 2011 The immunology of stroke: from mechanisms to translation. Nat. Med. 17:796–808. 10.1038/nm.239921738161, IadecolaC., and AnratherJ. 2011 The immunology of stroke: from mechanisms to translation. Nat. Med. 17:796–808. 10.1038/nm.239921738161
L. Sansing, T. Harris, S. Kasner, C. Hunter, K. Karikó (2011)
Neutrophil depletion diminishes monocyte infiltration and improves functional outcome after experimental intracerebral hemorrhage.Acta neurochirurgica. Supplement, 111
Ying Fu, Qiang Liu, J. Anrather, F. Shi (2015)
Immune interventions in strokeNature Reviews Neurology, 11
(UrdayS., BeslowL.A., DaiF., ZhangF., BatteyT.W., VashkevichA., AyresA.M., LeasureA.C., SelimM.H., SimardJ.M., 2016 Rate of Perihematomal Edema Expansion Predicts Outcome After Intracerebral Hemorrhage. Crit. Care Med. 44:790–797. 10.1097/CCM.000000000000155326757167)
UrdayS., BeslowL.A., DaiF., ZhangF., BatteyT.W., VashkevichA., AyresA.M., LeasureA.C., SelimM.H., SimardJ.M., 2016 Rate of Perihematomal Edema Expansion Predicts Outcome After Intracerebral Hemorrhage. Crit. Care Med. 44:790–797. 10.1097/CCM.000000000000155326757167UrdayS., BeslowL.A., DaiF., ZhangF., BatteyT.W., VashkevichA., AyresA.M., LeasureA.C., SelimM.H., SimardJ.M., 2016 Rate of Perihematomal Edema Expansion Predicts Outcome After Intracerebral Hemorrhage. Crit. Care Med. 44:790–797. 10.1097/CCM.000000000000155326757167, UrdayS., BeslowL.A., DaiF., ZhangF., BatteyT.W., VashkevichA., AyresA.M., LeasureA.C., SelimM.H., SimardJ.M., 2016 Rate of Perihematomal Edema Expansion Predicts Outcome After Intracerebral Hemorrhage. Crit. Care Med. 44:790–797. 10.1097/CCM.000000000000155326757167
Yao Zhang, Zhongming Gao, Dan-dan Wang, Tongshuai Zhang, Bo Sun, Lili Mu, Jinghua Wang, Yumei Liu, Qingfei Kong, Xi-jun Liu, Yueyang Zhang, Haoqiang Zhang, Jiqing He, Hulun Li, Guangyou Wang (2014)
Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10Journal of Neuroinflammation, 11
(ZhuJ., HuangX., and YangY. 2010 NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J. Immunol. 185:7480–7486. 10.4049/jimmunol.100277121076062)
ZhuJ., HuangX., and YangY. 2010 NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J. Immunol. 185:7480–7486. 10.4049/jimmunol.100277121076062ZhuJ., HuangX., and YangY. 2010 NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J. Immunol. 185:7480–7486. 10.4049/jimmunol.100277121076062, ZhuJ., HuangX., and YangY. 2010 NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J. Immunol. 185:7480–7486. 10.4049/jimmunol.100277121076062
(LeeK.R., KawaiN., KimS., SagherO., and HoffJ.T. 1997 Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J. Neurosurg. 86:272–278. 10.3171/jns.1997.86.2.02729010429)
LeeK.R., KawaiN., KimS., SagherO., and HoffJ.T. 1997 Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J. Neurosurg. 86:272–278. 10.3171/jns.1997.86.2.02729010429LeeK.R., KawaiN., KimS., SagherO., and HoffJ.T. 1997 Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J. Neurosurg. 86:272–278. 10.3171/jns.1997.86.2.02729010429, LeeK.R., KawaiN., KimS., SagherO., and HoffJ.T. 1997 Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J. Neurosurg. 86:272–278. 10.3171/jns.1997.86.2.02729010429
R. Keep, Y. Hua, G. Xi (2012)
Intracerebral haemorrhage: mechanisms of injury and therapeutic targetsThe Lancet Neurology, 11
(FuY., HaoJ., ZhangN., RenL., SunN., LiY.J., YanY., HuangD., YuC., and ShiF.D. 2014 Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 71:1092–1101. 10.1001/jamaneurol.2014.106525003359)
FuY., HaoJ., ZhangN., RenL., SunN., LiY.J., YanY., HuangD., YuC., and ShiF.D. 2014 Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 71:1092–1101. 10.1001/jamaneurol.2014.106525003359FuY., HaoJ., ZhangN., RenL., SunN., LiY.J., YanY., HuangD., YuC., and ShiF.D. 2014 Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 71:1092–1101. 10.1001/jamaneurol.2014.106525003359, FuY., HaoJ., ZhangN., RenL., SunN., LiY.J., YanY., HuangD., YuC., and ShiF.D. 2014 Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 71:1092–1101. 10.1001/jamaneurol.2014.106525003359
(FuY., LiuQ., AnratherJ., and ShiF.D. 2015 Immune interventions in stroke. Nat. Rev. Neurol. 11:524–535. 10.1038/nrneurol.2015.14426303850)
FuY., LiuQ., AnratherJ., and ShiF.D. 2015 Immune interventions in stroke. Nat. Rev. Neurol. 11:524–535. 10.1038/nrneurol.2015.14426303850FuY., LiuQ., AnratherJ., and ShiF.D. 2015 Immune interventions in stroke. Nat. Rev. Neurol. 11:524–535. 10.1038/nrneurol.2015.14426303850, FuY., LiuQ., AnratherJ., and ShiF.D. 2015 Immune interventions in stroke. Nat. Rev. Neurol. 11:524–535. 10.1038/nrneurol.2015.14426303850
É. Vivier, D. Raulet, A. Moretta, M. Caligiuri, L. Zitvogel, L. Lanier, W. Yokoyama, S. Ugolini (2011)
Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 331
A. Qureshi, A. Mendelow, Daniel Hanley (2009)
Intracerebral haemorrhageThe Lancet, 373
(MracskoE., JavidiE., NaS.Y., KahnA., LieszA., and VeltkampR. 2014 Leukocyte invasion of the brain after experimental intracerebral hemorrhage in mice. Stroke. 45:2107–2114. 10.1161/STROKEAHA.114.00580124916913)
MracskoE., JavidiE., NaS.Y., KahnA., LieszA., and VeltkampR. 2014 Leukocyte invasion of the brain after experimental intracerebral hemorrhage in mice. Stroke. 45:2107–2114. 10.1161/STROKEAHA.114.00580124916913MracskoE., JavidiE., NaS.Y., KahnA., LieszA., and VeltkampR. 2014 Leukocyte invasion of the brain after experimental intracerebral hemorrhage in mice. Stroke. 45:2107–2114. 10.1161/STROKEAHA.114.00580124916913, MracskoE., JavidiE., NaS.Y., KahnA., LieszA., and VeltkampR. 2014 Leukocyte invasion of the brain after experimental intracerebral hemorrhage in mice. Stroke. 45:2107–2114. 10.1161/STROKEAHA.114.00580124916913
(WangJ. 2010 Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog. Neurobiol. 92:463–477. 10.1016/j.pneurobio.2010.08.00120713126)
WangJ. 2010 Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog. Neurobiol. 92:463–477. 10.1016/j.pneurobio.2010.08.00120713126WangJ. 2010 Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog. Neurobiol. 92:463–477. 10.1016/j.pneurobio.2010.08.00120713126, WangJ. 2010 Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog. Neurobiol. 92:463–477. 10.1016/j.pneurobio.2010.08.00120713126
(KeepR.F., HuaY., and XiG. 2012 Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 11:720–731. 10.1016/S1474-4422(12)70104-722698888)
KeepR.F., HuaY., and XiG. 2012 Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 11:720–731. 10.1016/S1474-4422(12)70104-722698888KeepR.F., HuaY., and XiG. 2012 Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 11:720–731. 10.1016/S1474-4422(12)70104-722698888, KeepR.F., HuaY., and XiG. 2012 Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 11:720–731. 10.1016/S1474-4422(12)70104-722698888
(ShiF.D., LjunggrenH.G., La CavaA., and Van KaerL. 2011 Organ-specific features of natural killer cells. Nat. Rev. Immunol. 11:658–671. 10.1038/nri306521941294)
ShiF.D., LjunggrenH.G., La CavaA., and Van KaerL. 2011 Organ-specific features of natural killer cells. Nat. Rev. Immunol. 11:658–671. 10.1038/nri306521941294ShiF.D., LjunggrenH.G., La CavaA., and Van KaerL. 2011 Organ-specific features of natural killer cells. Nat. Rev. Immunol. 11:658–671. 10.1038/nri306521941294, ShiF.D., LjunggrenH.G., La CavaA., and Van KaerL. 2011 Organ-specific features of natural killer cells. Nat. Rev. Immunol. 11:658–671. 10.1038/nri306521941294
Adeline Crinier, P. Milpied, Bertrand Escalière, C. Pipéroglou, Justine Galluso, Anaïs Balsamo, Lionel Spinelli, Inaki Cervera-Marzal, M. Ebbo, M. Girard-Madoux, S. Jaeger, Emilie Bollon, S. Hamed, J. Hardwigsen, S. Ugolini, F. Vely, Émilie Narni-Mancinelli, É. Vivier (2018)
High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and MiceImmunity, 49
Minshu Li, Honglei Ren, K. Sheth, F. Shi, Qiang Liu (2017)
A TSPO ligand attenuates brain injury after intracerebral hemorrhageThe FASEB Journal, 31
(VivierE., RauletD.H., MorettaA., CaligiuriM.A., ZitvogelL., LanierL.L., YokoyamaW.M., and UgoliniS. 2011 Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 10.1126/science.119868721212348)
VivierE., RauletD.H., MorettaA., CaligiuriM.A., ZitvogelL., LanierL.L., YokoyamaW.M., and UgoliniS. 2011 Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 10.1126/science.119868721212348VivierE., RauletD.H., MorettaA., CaligiuriM.A., ZitvogelL., LanierL.L., YokoyamaW.M., and UgoliniS. 2011 Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 10.1126/science.119868721212348, VivierE., RauletD.H., MorettaA., CaligiuriM.A., ZitvogelL., LanierL.L., YokoyamaW.M., and UgoliniS. 2011 Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 10.1126/science.119868721212348
(KaurG., TrowsdaleJ., and FuggerL. 2013 Natural killer cells and their receptors in multiple sclerosis. Brain. 136:2657–2676. 10.1093/brain/aws15922734127)
KaurG., TrowsdaleJ., and FuggerL. 2013 Natural killer cells and their receptors in multiple sclerosis. Brain. 136:2657–2676. 10.1093/brain/aws15922734127KaurG., TrowsdaleJ., and FuggerL. 2013 Natural killer cells and their receptors in multiple sclerosis. Brain. 136:2657–2676. 10.1093/brain/aws15922734127, KaurG., TrowsdaleJ., and FuggerL. 2013 Natural killer cells and their receptors in multiple sclerosis. Brain. 136:2657–2676. 10.1093/brain/aws15922734127
(LongE.O., KimH.S., LiuD., PetersonM.E., and RajagopalanS. 2013 Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31:227–258. 10.1146/annurev-immunol-020711-07500523516982)
LongE.O., KimH.S., LiuD., PetersonM.E., and RajagopalanS. 2013 Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31:227–258. 10.1146/annurev-immunol-020711-07500523516982LongE.O., KimH.S., LiuD., PetersonM.E., and RajagopalanS. 2013 Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31:227–258. 10.1146/annurev-immunol-020711-07500523516982, LongE.O., KimH.S., LiuD., PetersonM.E., and RajagopalanS. 2013 Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31:227–258. 10.1146/annurev-immunol-020711-07500523516982
(AktasO., KüryP., KieseierB., and HartungH.P. 2010 Fingolimod is a potential novel therapy for multiple sclerosis. Nat. Rev. Neurol. 6:373–382. 10.1038/nrneurol.2010.7620551946)
AktasO., KüryP., KieseierB., and HartungH.P. 2010 Fingolimod is a potential novel therapy for multiple sclerosis. Nat. Rev. Neurol. 6:373–382. 10.1038/nrneurol.2010.7620551946AktasO., KüryP., KieseierB., and HartungH.P. 2010 Fingolimod is a potential novel therapy for multiple sclerosis. Nat. Rev. Neurol. 6:373–382. 10.1038/nrneurol.2010.7620551946, AktasO., KüryP., KieseierB., and HartungH.P. 2010 Fingolimod is a potential novel therapy for multiple sclerosis. Nat. Rev. Neurol. 6:373–382. 10.1038/nrneurol.2010.7620551946
(QureshiA.I., MendelowA.D., and HanleyD.F. 2009 Intracerebral haemorrhage. Lancet. 373:1632–1644. 10.1016/S0140-6736(09)60371-819427958)
QureshiA.I., MendelowA.D., and HanleyD.F. 2009 Intracerebral haemorrhage. Lancet. 373:1632–1644. 10.1016/S0140-6736(09)60371-819427958QureshiA.I., MendelowA.D., and HanleyD.F. 2009 Intracerebral haemorrhage. Lancet. 373:1632–1644. 10.1016/S0140-6736(09)60371-819427958, QureshiA.I., MendelowA.D., and HanleyD.F. 2009 Intracerebral haemorrhage. Lancet. 373:1632–1644. 10.1016/S0140-6736(09)60371-819427958
(BrinkmannV., BillichA., BaumrukerT., HeiningP., SchmouderR., FrancisG., AradhyeS., and BurtinP. 2010 Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9:883–897. 10.1038/nrd324821031003)
BrinkmannV., BillichA., BaumrukerT., HeiningP., SchmouderR., FrancisG., AradhyeS., and BurtinP. 2010 Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9:883–897. 10.1038/nrd324821031003BrinkmannV., BillichA., BaumrukerT., HeiningP., SchmouderR., FrancisG., AradhyeS., and BurtinP. 2010 Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9:883–897. 10.1038/nrd324821031003, BrinkmannV., BillichA., BaumrukerT., HeiningP., SchmouderR., FrancisG., AradhyeS., and BurtinP. 2010 Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9:883–897. 10.1038/nrd324821031003
D. Hanley, R. Thompson, M. Rosenblum, G. Yenokyan, K. Lane, N. McBee, S. Mayo, Amanda Bistran-Hall, D. Gandhi, W. Mould, N. Ullman, Hasan Ali, J. Carhuapoma, C. Kase, K. Lees, J. Dawson, Alastair Wilson, J. Betz, E. Sugar, Yi Hao, Radhika Avadhani, J. Caron, M. Harrigan, A. Carlson, D. Bulters, D. Ledoux, Judy Huang, Cully Cobb, G. Gupta, Ryan Kitagawa, M. Chicoine, H. Patel, R. Dodd, P. Camarata, S. Wolfe, Agnieszka Stadnik, P. Money, P. Mitchell, R. Sarabia, S. Harnof, P. Barzó, A. Unterberg, J. Teitelbaum, Weimin Wang, C. Anderson, A. Mendelow, B. Gregson, S. Janis, P. Vespa, W. Ziai, M. Zuccarello, I. Awad, Azmil Abdul-Rahim, A. Abou‐Hamden, M. Abraham, Azam Ahmed, C. Alba, E. Aldrich, D. Altschul, S. Amin‐Hanjani, Doug Anderson, Safdar Ansari, D. Antezana, A. Ardelt, F. Arikan, M. Báguena, A. Baker, S. Barrer, K. Becker, T. Bergman, A. Boström, Jamie Braun, P. Brindley, W. Broaddus, Robert Brown, A. Buki, B. Cao, Ying Cao, J. Carrión-Penagos, J. Chalela, Tiffany Chang, I. Chorro, S. Chowdhry, L. Corral, L. Csiba, J. Davies, A. Díaz, C. Derdeyn, Michael Diringer, R. Dlugash, R. Ecker, Tracey Economas, P. Enríquez, E. Ezer, Yuhua Fan, H. Feng, Douglas Franz, W. Freeman, M. Fusco, W. Galicich, Mary Gelea, J. Goldstein, Alejandro Gonzalez, C. Grabarits, S. Greenberg, D. Gress, E. Gu, C. Hall, F. Hernández, R. Hoesch, B. Hoh, J. Houser, Rong Hu, Yi Huang, M. Hussain, Salvatore Insinga, A. Jadhav, Jennifer Jaffe, B. Jahromi, J. Jallo, M. James, R. James, B. Jankowitz, E.-S. Jeon, D. Jichici, K. Jonczak, B. Jonker, Nicole Karlen, N. Keric, T. Kerz, J. Knopman, Carolyn Koenig, S. Krishnamurthy, Avinash Kumar, I. Kureshi, J. Laidlaw, A. Lakhanpal, J. Latorre, D. Leifer, J. Leiphart, S. Lenington, Yunke Li, G. Lopez, D. Lovick, C. Lumenta, Jinbiao Luo, M. Maas, J. Macdonald, L. Mackenzie, Vikram Madan, R. Majkowski, O. Major, Rishi Malhorta, M. Malkoff, H. Mangat, Ahmed Maswadeh, C. Matouk, K. McArthur, S. McCaul, J. Medow, G. Mezey, Janet Mighty, David Miller, Krishna Mohan, K. Muir, Lorenzo Muñoz, P. Nakaji, Alex Nee, S. Nekoovaght-Tak, P. Nyquist, R. O'kane, M. Okasha, C. O’Kelly, N. Ostapkovich, A. Pandey, A. Parry-Jones, Krissia Perla, A. Pollack, S. Polster, N. Pouratian, T. Quinn, V. Rajajee, Kesava Reddy, Mohammed Rehman, R. Reimer, F. Rincon, I. Rybinnik, Baltasar Sánchez, L. Sansing, Michaela Schneck, L. Schuerer, D. Schul, Jeffrey Schweitzer, David Seder, D. Seyfried, K. Sheth, A. Spiotta, M. Stechison, K. Szabo, Gonzalo Tamayo, K. Tánczos, P. Taussky, J. Terry, F. Testai, K. Thomas, C. Thompson, G. Thompson, J. Torner, Huy Tran, Kristi Tucker, L. Ungar, P. Varelas, N. Vargas, H. Vatter, C. Venkatasubramanian, Krista Vermillion, D. Vollmer, Yan Wang, Ying Wang, Jiajun Wen, Louis Whitworth, Byron Willis, Myriha Wrencher, Shawn Wright, Yong-Ping Xu, L. Yanase, Xuxia Yi, Zhiyuan Yu, A. Zomorodi (2019)
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trialThe Lancet, 393
Y. Gan, Qiang Liu, Wei Wu, Jun-xiang Yin, X. Bai, Rulong Shen, Yongjun Wang, Jieli Chen, A. Cava, Jennifer Poursine‐Laurent, W. Yokoyama, F. Shi (2014)
Ischemic neurons recruit natural killer cells that accelerate brain infarctionProceedings of the National Academy of Sciences, 111
(RenH., KongY., LiuZ., ZangD., YangX., WoodK., LiM., and LiuQ. 2018 Selective NLRP3 (Pyrin Domain-Containing Protein 3) Inflammasome Inhibitor Reduces Brain Injury After Intracerebral Hemorrhage. Stroke. 49:184–192. 10.1161/STROKEAHA.117.01890429212744)
RenH., KongY., LiuZ., ZangD., YangX., WoodK., LiM., and LiuQ. 2018 Selective NLRP3 (Pyrin Domain-Containing Protein 3) Inflammasome Inhibitor Reduces Brain Injury After Intracerebral Hemorrhage. Stroke. 49:184–192. 10.1161/STROKEAHA.117.01890429212744RenH., KongY., LiuZ., ZangD., YangX., WoodK., LiM., and LiuQ. 2018 Selective NLRP3 (Pyrin Domain-Containing Protein 3) Inflammasome Inhibitor Reduces Brain Injury After Intracerebral Hemorrhage. Stroke. 49:184–192. 10.1161/STROKEAHA.117.01890429212744, RenH., KongY., LiuZ., ZangD., YangX., WoodK., LiM., and LiuQ. 2018 Selective NLRP3 (Pyrin Domain-Containing Protein 3) Inflammasome Inhibitor Reduces Brain Injury After Intracerebral Hemorrhage. Stroke. 49:184–192. 10.1161/STROKEAHA.117.01890429212744
E. Mracsko, R. Veltkamp (2014)
Neuroinflammation after intracerebral hemorrhageFrontiers in Cellular Neuroscience, 8
Qiang Liu, Wei-Na Jin, Yaou Liu, Kaibin Shi, Haoran Sun, Fangyi Zhang, Chao Zhang, R. Gonzales, K. Sheth, A. Cava, F. Shi (2017)
Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic InnervationsImmunity, 46
Perihematomal edema (PHE) occurs within hours after intracerebral hemorrhage (ICH), leading to secondary injury manifested by impaired blood–brain barrier (BBB) integrity and destruction of adjacent tissue. To dissect the mechanisms underlying PHE formation, we profiled human and mouse perihematomal tissues and identified natural killer (NK) cells as the predominant immune cell subset that outnumbers other infiltrating immune cell types during early stages of ICH. Unbiased clustering of single-cell transcriptional profiles revealed two major NK cell subsets that respectively possess high cytotoxicity or robust chemokine production features in the brain after ICH, distinguishing them from NK cells of the periphery. NK cells exacerbate BBB disruption and brain edema after ICH via cytotoxicity toward cerebral endothelial cells and recruitment of neutrophils that augment focal inflammation. Thus, brain-bound NK cells acquire new features that contribute to PHE formation and neurological deterioration following ICH.
The Journal of Experimental Medicine – Rockefeller University Press
Published: Dec 7, 2020
Keywords: cerebral hemorrhage,cerebral edema,natural killer cells,brain,mice,symptom aggravating factors,neurologic deterioration,cytotoxicity
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.